NatWest shares plunge as bank cuts guidance and admits 'serious failings' in treatment of Brexit campaigner Nigel Farage
By Louis Goss
Farage slams report as a 'whitewash'
Shares in NatWest Group PLC (UK:NWG) fell 12% on Friday after the British bank cut its guidance and admitted "serious failings" in its treatment of Brexit campaigner Nigel Farage following the closure of his account with its private-banking subsidiary, Coutts.
NatWest's chair, Howard Davies, apologized to the former U.K. Independence Party leader following the publication of an independent report by law firm Travers Smith that identified "clear shortcomings" in the bank's handling of the Farage matter.
The report, which was commissioned by the bank, said that while the decision to close Farage's account had been lawful, NatWest failed to properly communicate the reasons for the closure, instead telling the Brexit campaigner it was done solely for commercial reasons.
The law firm's review also said the decision by former NatWest CEO Allison Rose to leak confidential information about Farage to a BBC journalist could amount to a breach of privacy rules. It noted that any verdict on this is now a matter for U.K. regulators.
Farage slammed the report as a "whitewash" as he hit out at claims in the document that the decision to close his account was not in itself a political decision. Farage noted that the word Brexit appeared 86 times in documents he obtained from NatWest via a Subject Access Request.
NatWest separately confirmed that the U.K.'s Financial Conduct Authority has now launched a review into its governance and control systems, after Britain's Information Commissioner's Office earlier this week ruled that Rose had breached Farage's privacy.
The negative impact of the report on NatWest's share price was exacerbated by the bank on Friday lowering its full-year income guidance, from GBP14.8 billion (equivalent to $18 billion) to GBP14.3 billion ($17.4 billion). The combined hits saw NatWest's share price drop to 30-month lows.
Elsewhere in Europe, shares in Sanofi SA (FR:SAN) plunged 17% after the French drugmaker cut its guidance for 2025 due to higher spending on research and development and to higher taxes.
The pharmaceutical company said it plans to spin off its consumer-healthcare unit and invest in the development of new vaccines and medicines. Sanofi also said it expects its tax rate to increase from 19% in 2023 to 21% in 2024.
Shares in cognac maker Rémy Cointreau SA (FR:RCO), which owns brands including Rémy Martin, fell 12% after the Parisian company lowered its profit guidance due to worsening market conditions in the U.S. and a slower-than-expected post-COVID recovery in China.
The STOXX Europe 600 index (FXXP00) stayed flat on Friday following the European Central Bank's decision on Thursday to leave interest rates unchanged, following a series of 10 consecutive rate hikes. ECB President Christine Lagarde, however, did not rule out the possibility of future hikes.
-Louis Goss
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-27-23 0955ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom